2026-02-12
ImmuneOnco Announces NMPA Approval of Clinical Trial Application for Amouravfop alfa (IMM0306) in the Treatment of IgG4-Related Disease
In parallel, ImmuneOnco has recently submitted an IND application to the NMPA for a subcutaneous formulation of IMM0306, which has been accepted for review. This next-generation delivery method aims to enhance patient convenience and long-term treatment adherence. Combined with prior clinical trial progress or IND submissions across multiple immune-mediated indications—including relapsed/refractory follicular lymphoma (in combination with lenalidomide; Phase III approved), SLE (Phase Ib/II), neuromyelitis optica spectrum disorder (NMOSD; Phase Ib/III), lupus nephritis (LN; Phase II), and primary membranous nephropathy (PMN; IND accepted)—the systematic advancement of IMM0306 in autoimmune diseases underscores the broad therapeutic potential of the CD47×CD20 dual-target mechanism and establishes a solid platform for future expansion into additional autoimmune conditions.
View more
2026-01-28
ImmuneCare, a Subsidiary of ImmuneOnco, Files Patent for IMC-015 Bispecific Antibody Differentiated "Fat-Loss & Muscle-Gain" Strategy Poised to Tackle GLP-1-Induced Muscle Loss
Shanghai, China, 28 January 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,
View more
2026-01-19
ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension
Shanghai, China, January 19, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,
View more
